The Anterior Uveitis drugs in development market research report provides comprehensive information on the therapeutics under development for Anterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Anterior Uveitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Anterior Uveitis and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Anterior Uveitis by ten companies/universities/institutes. The top development phase for Anterior Uveitis is preclinical with four drugs in that stage. The Anterior Uveitis pipeline has nine drugs in development by companies and one by universities/ institutes. Some of the companies in the Anterior Uveitis pipeline products market are: Eyevensys, Louisiana State University Health Sciences Center New Orleans and Elasmogen.
The key targets in the Anterior Uveitis pipeline products market include Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF), Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A), and Toll Like Receptor Family (TLR).
The key mechanisms of action in the Anterior Uveitis pipeline product include Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor with four drugs in Pre-Registration. The Anterior Uveitis pipeline products include three routes of administration with the top ROA being Ophthalmic and four key molecule types in the Anterior Uveitis pipeline products market including Monoclonal Antibody, and Small Molecule.
Anterior Uveitis overview
Inflammation of the eyes is known as Uveitis. If inflammation occurs at the anterior portion of the eye (iris) it is known as anterior uveitis. Uveitis damages the uvea, the middle layer of the eye consisting of the iris, ciliary body, and choroid. Common causes are any trauma to the eye, underlying health issues like diabetes, viral infections HSV, syphilis, TB, and other causes. Redness, itchiness, blurred vision, and sensitivity to light are common symptoms. This condition can be acute or chronic if left untreated or prevented. Glaucoma, cataract are complications associated with this. Anti-inflammatory drugs as eye drops, injections, are prescribed. Steroid induced glaucoma can result in uveitis hence not recommended in complicated cases.
For a complete picture of Anterior Uveitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
